| 4 | The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification显示文摘Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients. | Shanshan LI Wenyu GNOG Sibo HUANG Lianghong YIN Bo HU Xiangnan DONG Taksui WONG Fanna LIU Yingyan LI Yueling ZHU Xin CHEN Baozhang GUAN Shengling HUANG Shuang CUI Bing YAN Hongwei HU Shaofeng HUANG Yongpin LU Shufei ZENG Chen YUN Berthold Hocher Wolfgang Pomme | 2017 | 临床医学工程2017，24，S1： | 0 |
| 5 | Efficacy and Safety of Febuxost at in the Treatment of Chronic Kidney Disease with Hyperuricemia: A Meta- Analysis显示文摘Background Febuxostat and allopurinol have different pharmacological mechanisms,the efficacy of febuxostat in chronic kidney disease complicated with hyperuricemia remains controversial.A meta-analysis and systemic review was conducted to investigate the efficacy and safety of febuxostat in CKD populations complicated with hyperuricemia.Methods A comprehensive search was conducted in multiple electronic databases based on the inclusion and exclusion criteria,before December 2016,searching for the published studies,including Chinese and English,relating to the use of febuxostat in CKD populations complicated with hyperuricemia,and manual retrieval of the inclusion literature.Literature evaluation and data extraction were performed by two reviewers,Rev Man 5.3 was used to perform the meta-analysis.Results Seven studies with 482 CKD patients were included in the meta-analysis.We found that febuxostat can significantly slow the decreasing speed of e GFR[RR=4.90,95%CI(1.95,7.84),P=0.001],and reduce serum uric acid[RR=-99.30,95%CI(-172.24,-26.37),P=0.008]levels in CKD patients complicated with hyperuricemia when compairing with control group.There was no significant difference in the levels of systolic blood pressure[RR=-2.19,95%CI(-9.99,5.61),P=0.58],diastolic blood pressure[RR=-2.30,95%CI(-7.33,2.73),P=0.10],low density lipoprotein[RR=-0.47,95%CI(-7.64,6.69),P=0.90]between the two groups.Compared with the control group,the use of febuxostat increase the incidence of adverse reaction[RR=4.73,95%CI(1.04,21.43),P=0.04]in patients.Conclusions Febuxostat can significantly lower serum uric acid level and effectively delay the process of chronic renal failure in CKD patients complicated with hyperuricemic,increases the incidence of adverse reaction,no significant difference in SBP,DBP,LDL,when compared with control group. | Jingyun Ou Bin Yan Shenling Huang Mingming Ma Jun Ke Hongwei Hu Sibo Huang Xiangnan Dong Aiyun Cha Zuhui Chen Yu Mong Fanna Liu W.Pommer Chen Yun Yongpin Lu Shufei Zeng Lianghong Yin B.Hocher | 2017 | 临床医学工程2017，24，S1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员